Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Not Recruiting

Trial ID: NCT02182986


Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

Official Title

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (CTOTC-06)

Stanford Investigator(s)

Carlos O. Esquivel, M.D., Ph.D.,FACS
Carlos O. Esquivel, M.D., Ph.D.,FACS

Arnold and Barbara Silverman Professor in Pediatric Transplantation and Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Gastroenterology, Hepatology and Nutrition)


Inclusion Criteria:

* Subject and/or parent or legal guardian must be able to understand and provide informed consent/assent;
* Candidate for or recipient of: heart, liver, heart with liver, small intestine, liver with small intestine, or kidney; and
* Subject enrolled within 3 years of transplant.

Exclusion Criteria:

* Previous diagnosis of PTLD;
* Transplant recipients of lung alone, or in combination with an eligible organ type;
* Pancreas transplantation with the exception of 'en bloc' transplant in combined liver and small intestine multivisceral transplantation;
* Any combination other than listed in inclusion criteria;
* History of any previous solid organ, stem cell, or bone marrow transplantation;
* Inability or unwillingness of the legal guardian and/or the subject to comply with the study protocol.


procedure: transplant

drug: Immunosuppressive Drugs

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sheri Krams, PhD